The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
about
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsOverexpression of heat-shock factor 1 is associated with a poor prognosis in esophageal squamous cell carcinomaCharacterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsGastrointestinal stromal tumor - an evolving concept.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.Update on imatinib for gastrointestinal stromal tumors: duration of treatment.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.GIST treatment options after tyrosine kinase inhibitors.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.Gastrointestinal stromal tumors
P2860
Q26799387-4763882C-D65A-4D40-918B-BA48EAB6A66BQ33597951-3D5E7563-1D28-4FC3-9904-856E9AF9FB4EQ34052411-EA0A1026-733E-4641-8AA9-BBC2D5015A8EQ34289180-5834FFF1-C797-4EEA-98C4-A932F66270E2Q34677194-C174F483-111A-4EB3-9CBA-05AF70F38AF6Q34928165-D8D313DF-0D4D-4A9C-9F20-779AB8F75708Q36125976-D84A6A02-C11E-4CA4-BBA3-39ABCFCFAD2CQ36546425-5D14BB26-0264-4899-9ABE-ED7C58E59EC9Q37075052-1611355C-4ACF-4557-8E1F-F2637D3EB9D9Q37220191-032A50A2-D0D3-4773-8818-6FB5A666D879Q37327734-59BA8717-9FBA-414F-9A99-7CD280CE4698Q38222205-3E02BE63-FFE2-4C39-934A-797CDE1FC68BQ38737681-DFAC74D5-A863-4314-84A1-66935F0B0C18Q39166835-2499E158-3920-44D6-A5D4-4E8D5991BB43Q39288497-B5D0938E-DE03-4F7E-A4E3-C13636416AE3Q47355982-CD81A26D-78AC-4964-A6AA-FCB606722C2BQ47432725-715A633B-8417-4672-8197-BC01218EE0EAQ54976637-8DD86F14-D268-4797-9F28-94B4FF9235B1Q57649696-FED15C99-9DB3-4FDB-96FC-55E582E53C5F
P2860
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The HSP90 inhibitor, AT13387, ...... testinal stromal tumor models.
@en
type
label
The HSP90 inhibitor, AT13387, ...... testinal stromal tumor models.
@en
prefLabel
The HSP90 inhibitor, AT13387, ...... testinal stromal tumor models.
@en
P2093
P2860
P1476
The HSP90 inhibitor, AT13387, ...... testinal stromal tumor models.
@en
P2093
Agnieszka Wozniak
Ana M Rodriguez-Lopez
Jayne E Curry
Jennifer G Morgan
John Lyons
Jonathan A Fletcher
Mark Mayeda
Meijun Zhu
Neil T Thompson
Nicola G Wallis
P2860
P304
P356
10.1158/1535-7163.MCT-11-1046
P577
2012-06-19T00:00:00Z